Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies
- PMID: 32008852
- PMCID: PMC7856568
- DOI: 10.1016/j.tips.2019.12.008
Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies
Abstract
A variety of G protein-coupled receptors (GPCRs) have been implicated in the pathogenesis of pulmonary fibrosis, largely through their promotion of profibrotic fibroblast activation. By contrast, recent work has highlighted the beneficial effects of Gαs-coupled GPCRs on reducing fibroblast activation and fibrosis. This review highlights how fibrosis-promoting and -inhibiting GPCR signaling converges on downstream signaling and transcriptional effectors, and how the diversity and dynamics of GPCR expression challenge efforts to identify effective therapies for idiopathic pulmonary fibrosis (IPF). Next-generation strategies to overcome these challenges, focusing on target selection, polypharmacology, and personalized medicine approaches, are discussed as a path towards more effective GPCR-targeted therapies for pulmonary fibrosis.
Keywords: G protein-coupled receptor; MRTF; ROCK; TAZ; YAP; fibrosis.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
GPCRs and fibroblast heterogeneity in fibroblast-associated diseases.FASEB J. 2023 Aug;37(8):e23101. doi: 10.1096/fj.202301091. FASEB J. 2023. PMID: 37486603 Free PMC article. Review.
-
The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ.Am J Respir Cell Mol Biol. 2019 May;60(5):578-591. doi: 10.1165/rcmb.2018-0142OC. Am J Respir Cell Mol Biol. 2019. PMID: 30537446
-
TBK1 regulates YAP/TAZ and fibrogenic fibroblast activation.Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L852-L863. doi: 10.1152/ajplung.00324.2019. Epub 2020 Mar 11. Am J Physiol Lung Cell Mol Physiol. 2020. PMID: 32159970 Free PMC article.
-
GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1.PLoS One. 2020 Feb 13;15(2):e0228195. doi: 10.1371/journal.pone.0228195. eCollection 2020. PLoS One. 2020. PMID: 32053631 Free PMC article.
-
The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.Pharmacol Rev. 2015;67(1):103-17. doi: 10.1124/pr.114.009381. Pharmacol Rev. 2015. PMID: 25395505 Free PMC article. Review.
Cited by
-
Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases.Curr Opin Pharmacol. 2020 Apr;51:34-42. doi: 10.1016/j.coph.2020.05.002. Epub 2020 Jul 1. Curr Opin Pharmacol. 2020. PMID: 32622335 Free PMC article. Review.
-
GPCRs and fibroblast heterogeneity in fibroblast-associated diseases.FASEB J. 2023 Aug;37(8):e23101. doi: 10.1096/fj.202301091. FASEB J. 2023. PMID: 37486603 Free PMC article. Review.
-
Dopamine D1 receptor stimulates cathepsin K-dependent degradation and resorption of collagen I in lung fibroblasts.J Cell Sci. 2020 Dec 11;133(23):jcs248278. doi: 10.1242/jcs.248278. J Cell Sci. 2020. PMID: 33172983 Free PMC article.
-
Targeting GPCRs to treat cardiac fibrosis.Front Cardiovasc Med. 2022 Oct 6;9:1011176. doi: 10.3389/fcvm.2022.1011176. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36277752 Free PMC article. Review.
-
Endothelial upregulation of mechanosensitive channel Piezo1 in pulmonary hypertension.Am J Physiol Cell Physiol. 2021 Dec 1;321(6):C1010-C1027. doi: 10.1152/ajpcell.00147.2021. Epub 2021 Oct 20. Am J Physiol Cell Physiol. 2021. PMID: 34669509 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources